JP2013515004A - 安定な液体薬剤のための方法および組成物 - Google Patents

安定な液体薬剤のための方法および組成物 Download PDF

Info

Publication number
JP2013515004A
JP2013515004A JP2012544920A JP2012544920A JP2013515004A JP 2013515004 A JP2013515004 A JP 2013515004A JP 2012544920 A JP2012544920 A JP 2012544920A JP 2012544920 A JP2012544920 A JP 2012544920A JP 2013515004 A JP2013515004 A JP 2013515004A
Authority
JP
Japan
Prior art keywords
protein
composition
agent
group
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515004A5 (pt
Inventor
レイトン，ハリー，ジェー．
フランガキス，クリスト，ジェー．
Original Assignee
エクソドス ライフ サイエンシーズ リミテッド パートナーシップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクソドス ライフ サイエンシーズ リミテッド パートナーシップ filed Critical エクソドス ライフ サイエンシーズ リミテッド パートナーシップ
Publication of JP2013515004A publication Critical patent/JP2013515004A/ja
Publication of JP2013515004A5 publication Critical patent/JP2013515004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012544920A 2009-12-18 2010-12-17 安定な液体薬剤のための方法および組成物 Pending JP2013515004A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28798809P 2009-12-18 2009-12-18
US61/287,988 2009-12-18
PCT/US2010/061135 WO2011075691A1 (en) 2009-12-18 2010-12-17 Methods and compositions for stable liquid drug formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015201055A Division JP2016053038A (ja) 2009-12-18 2015-10-09 安定な液体薬剤のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2013515004A true JP2013515004A (ja) 2013-05-02
JP2013515004A5 JP2013515004A5 (pt) 2014-02-06

Family

ID=44167729

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012544920A Pending JP2013515004A (ja) 2009-12-18 2010-12-17 安定な液体薬剤のための方法および組成物
JP2015201055A Pending JP2016053038A (ja) 2009-12-18 2015-10-09 安定な液体薬剤のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015201055A Pending JP2016053038A (ja) 2009-12-18 2015-10-09 安定な液体薬剤のための方法および組成物

Country Status (10)

Country Link
US (2) US9629920B2 (pt)
EP (1) EP2512460A4 (pt)
JP (2) JP2013515004A (pt)
CN (1) CN102802617B (pt)
AU (1) AU2010330750B2 (pt)
BR (1) BR112012014962A2 (pt)
CA (1) CA2784826A1 (pt)
IL (1) IL220465A (pt)
RU (1) RU2589697C2 (pt)
WO (1) WO2011075691A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180097611A (ko) * 2015-12-08 2018-08-31 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
WO2014008465A2 (en) * 2012-07-05 2014-01-09 The Research Foundation For The State University Of New York Potentiation of antibiotic treatment with a protein-lipid complex
KR102457026B1 (ko) * 2013-11-05 2022-10-21 신애질 코포레이션 입을 통한 연속적 약물 전달
EP2838510B1 (en) 2013-11-08 2016-09-21 Eli Lilly and Company Atomoxetine solution
US20170266106A1 (en) 2014-12-01 2017-09-21 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
CN107847722B (zh) 2015-05-06 2021-05-18 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
AU2018333058A1 (en) * 2017-09-15 2020-03-12 Gojo Industries, Inc. Antimicrobial composition
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN109212176B (zh) * 2018-08-30 2019-10-11 中拓生物有限公司 一种丙酮酸测定试剂盒及其制备方法和应用
CN113056282A (zh) * 2018-09-05 2021-06-29 文特里亚生物科学公司 免疫球蛋白a的制剂
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
JPH05238947A (ja) * 1992-02-28 1993-09-17 Yakult Honsha Co Ltd 細菌毒素中和剤
JPH11258236A (ja) * 1998-03-09 1999-09-24 Sekisui Chem Co Ltd 抗リン脂質抗体測定試薬
JP2001508806A (ja) * 1997-09-18 2001-07-03 フマン・エル・テー 血漿タンパク質含有医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006457A1 (en) * 1987-03-04 1988-09-07 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
ATE236657T1 (de) 1997-05-09 2003-04-15 Deutsches Krebsforsch Konjugat, umfassend einen folsäureantagonisten und einen träger
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
AU5241199A (en) * 1998-07-30 2000-02-21 Novopharm Biotech Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
KR100675809B1 (ko) * 1999-07-09 2007-02-01 오르토-맥네일 파마슈티칼, 인코퍼레이티드 맛을 차폐시킨 약제학적 액체 제제
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
PT2256134E (pt) 2003-11-13 2014-03-05 Hanmi Science Co Ltd Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
MXPA06014031A (es) 2004-06-01 2007-10-08 Domantis Ltd Anticuerpos de fusion biespecificos con vida media de serica mejorada.
DE102004057196A1 (de) 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
EA015277B1 (ru) 2008-04-22 2011-06-30 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Конъюгат 28-норбрассинолида с бычьим сывороточным альбумином в качестве иммуногена
AU2010330812B2 (en) 2009-12-18 2016-03-10 Exodos Life Sciences Limited Partnership Methods and compositions for treating inflammation of skin
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
EP2512240B1 (en) 2009-12-18 2018-04-11 Achelios Therapeutics, Inc. Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
JPH05238947A (ja) * 1992-02-28 1993-09-17 Yakult Honsha Co Ltd 細菌毒素中和剤
JP2001508806A (ja) * 1997-09-18 2001-07-03 フマン・エル・テー 血漿タンパク質含有医薬組成物
JPH11258236A (ja) * 1998-03-09 1999-09-24 Sekisui Chem Co Ltd 抗リン脂質抗体測定試薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 19(7), JPN6014034577, 1993, pages 843 - 852, ISSN: 0002877587 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 80(5), JPN6014034578, 1991, pages 484 - 487, ISSN: 0002877588 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180097611A (ko) * 2015-12-08 2018-08-31 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소

Also Published As

Publication number Publication date
CA2784826A1 (en) 2011-06-23
RU2589697C2 (ru) 2016-07-10
AU2010330750B2 (en) 2015-10-01
AU2010330750A1 (en) 2012-08-02
US20130071412A1 (en) 2013-03-21
WO2011075691A1 (en) 2011-06-23
IL220465A0 (en) 2012-08-30
CN102802617B (zh) 2016-05-11
EP2512460A4 (en) 2015-01-21
US9629920B2 (en) 2017-04-25
RU2012130391A (ru) 2014-01-27
JP2016053038A (ja) 2016-04-14
IL220465A (en) 2017-03-30
BR112012014962A2 (pt) 2016-04-05
EP2512460A1 (en) 2012-10-24
CN102802617A (zh) 2012-11-28
US20170224834A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
JP2016053038A (ja) 安定な液体薬剤のための方法および組成物
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
ES2728948T3 (es) Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina
JP4878732B2 (ja) 規制物質の濫用を防ぐための新規な持続放出製薬化合物
US7772222B2 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
ES2364865T3 (es) Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
JP7034078B2 (ja) セラストロールの類似体
JP6588962B2 (ja) 神経疾患を治療するための方法
US20110015182A1 (en) Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
JP2002504519A (ja) 新規なペプチド共重合体組成物
US20090291129A1 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
JP2002522357A5 (pt)
JP2018531289A6 (ja) セラストロールの類似体
JP2019023219A (ja) Ｍｅｔａｐ２阻害剤及び肥満症の治療方法
US20150031632A1 (en) Orally Disintegrating Compositions of Linaclotide
JP2018138605A (ja) 経皮吸収促進剤及び経皮吸収促進助剤
US20230128252A1 (en) Pharmaceutical compositions
Yong et al. Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects
EP1991248B1 (en) Antidepressant prodrugs
Cetin et al. Preparation and characterization of salmon calcitonin–biotin conjugates
MX2012011445A (es) Formulacion de pelicula oral.
CN114746092A (zh) D-***化合物、组合物、以及制备和使用它们的方法
JP7211603B2 (ja) 薬物送達用組成物および医薬組成物
Jacob et al. An updated overview of the emerging role of patch and film-based buccal delivery systems. Pharmaceutics. 2021; 13: 1206
CN101460496A (zh) 单和二取代的羟考酮化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151209

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160108